

European Heart Journal Supplements

Volume 24 Supplement D June 2022

Foreword: Acute optimization of heart rate in atrial fibrillation: landiolol as a first line therapy <i>G.-A. Dan</i>	D1
Acute rate control in atrial fibrillation: an urgent need for the clinician <i>G.-A. Dan, A.R. Dan, A. Ivanescu, and A.C. Buzea</i>	D3
Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure <i>T. Shiga</i>	D11
The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature <i>S. Bezati, M. Velliou, E. Polyzogopoulou, A. Bouladakis, and J. Parissis</i>	D22
Short acting intravenous beta-blocker as a first line of treatment for atrial fibrillation after cardiac surgery: a prospective observational study <i>X. Chapalain, J.F. Oilleau, L. Henaff, P. Lorillon PharmD, D. L. Saout, P. Kha, K. Pluchon, E. Bezon, and O. Huet</i>	D34
Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports <i>C. Gangl, K.A. Krychtiuk, R. Schoenbauer, and W.S. Speidl</i>	D43

